Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-y1)-3-arylpropanoic acid derivatives

1. A method of treating a condition selected from the group consisting of bone resorption, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, cancer, tumor growth, and metastasis; eliciting an αvβ3 integrin receptor antagonizing effect wherein the effect is inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, tumor growth, or metastasis; or inhibiting bone resorption in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein

X is selected from CH and N;

Y is selected from CH and N;

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms; and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula I contains at least one fluorine atom.

2. The method of claim 1 , comprising administering to the subject a therapeutically effective amount of a compound of formula II:

or a pharmaceutically acceptable salt or solvate thereof, wherein

X is selected from CH and N;

Y is selected from CH and N;

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms; and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula II contains at least one fluorine atom.

3. The method of claim 2 , comprising administering to the subject a therapeutically effective amount of a compound of formula III:

or a pharmaceutically acceptable salt or solvate thereof, wherein

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms; and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula III contains at least one fluorine atom.

4. The method of claim 2 , comprising administering to the subject a therapeutically effective amount of a compound of formula IV:

or a pharmaceutically acceptable salt or solvate thereof, wherein

R 1 is C 1 -C 6 alkoxy wherein said C i -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms; and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula IV contains at least one fluorine atom.

5. The method of claim 2 , comprising administering to the subject a therapeutically effective amount of a compound of formula V:

or a pharmaceutically acceptable salt or solvate thereof, wherein

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms; and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula V contains at least one fluorine atom.

6. The method of claim 1 , wherein the compound is administered orally, intravenously, intraperitoneally, topically, subcutaneously, intramuscularly, or transdermally.

7. The method of claim 6 , wherein the compound is administered topically.

8. The method of claim 1 , further comprising administering a second therapy.

9. The method of claim 8 , wherein the second therapy comprises an active ingredient selected from the group consisting of:

a) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof,

b) an estrogen receptor modulator,

c) a cytotoxic/antiproliferative agent,

d) a matrix metalloproteinase inhibitor,

e) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors,

f) an inhibitor of VEGF,

g) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tic-1,

h) a cathepsin K inhibitor, and

i) a prenylation inhibitor;

and mixtures thereof.

10. The method of claim 9 , wherein the second therapy comprises administering an inhibitor of VEGF.

11. The method of claim 1 , comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt or solvate thereof.

12. The method of claim 1 , comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt or solvate thereof.

13. The method of claim 1 , wherein the condition is selected from the group consisting of cancer and osteoporosis.

14. The method of claim 1 , wherein the condition is osteoporosis.

15. The method of claim 1 , wherein the method is treating a condition selected from the group consisting of bone resorption, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, cancer, tumor growth, and metastasis.

16. The method of claim 15 , wherein the condition is diabetic retinopathy or macular degeneration.

17. The method of claim 15 , wherein the condition is cancer.

18. The method of claim 1 , wherein the method is eliciting an αvβ3 integrin receptor antagonizing effect wherein the effect is inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, tumor growth, or metastasis.

19. The method of claim 18 , wherein the effect is inhibition of diabetic retinopathy or macular degeneration.

20. The method of claim 1 , wherein the method is inhibiting bone resorption.